Detalles de la búsqueda
1.
Health-related quality of life in patients with generalized pustular psoriasis: A systematic literature review.
J Eur Acad Dermatol Venereol;
38(2): 265-280, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37750484
2.
Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.
Br J Dermatol;
185(6): 1124-1134, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33913511
3.
Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2).
Br J Dermatol;
184(4): 652-662, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32652544
4.
Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies.
Br J Dermatol;
184(4): 640-651, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32531798
5.
Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial.
Br J Dermatol;
182(4): 889-899, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31286480
6.
Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.
Br J Dermatol;
180(1): 67-75, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30188571
7.
Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa.
Br J Dermatol;
181(3): 483-491, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30724351
8.
Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials.
J Eur Acad Dermatol Venereol;
33(3): 546-552, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30242918
9.
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
Br J Dermatol;
179(2): 320-328, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29488226
10.
A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process.
Br J Dermatol;
179(3): 642-650, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29654696
11.
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis.
Br J Dermatol;
179(4): 844-852, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29747232
12.
Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II.
Br J Dermatol;
178(3): 715-721, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29080368
13.
Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.
J Eur Acad Dermatol Venereol;
32(8): 1305-1313, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29512200
14.
Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
J Eur Acad Dermatol Venereol;
31(3): 477-482, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-27910156
15.
Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
J Eur Acad Dermatol Venereol;
31(4): 679-685, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27696577
16.
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
Br J Dermatol;
175(2): 273-86, 2016 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26914406
17.
Older adults on systemic treatment for psoriasis and risk of infection: a propensity score-matched population-based study.
Br J Dermatol;
183(3): 564-566, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32159850
18.
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
Br J Dermatol;
172(2): 484-93, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25132411
19.
Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo.
Br J Dermatol;
173(3): 641-50, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26149498
20.
Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor.
Br J Dermatol;
173(4): 989-97, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26123031